* International expertise to lead SAIK-MS effect studies (Phase II)
* Permission to start TTS Phase II trials in the UK expected shortly (renal cancer)
* Progress in the cooperation with the Johns Hopkins University in the US on prostate cancer - substance shows a significant anti-tumour effect in experimental models
* Capital gains on the sale of SBL Vaccin amounted to SEK 342 million
* Profit after financial items for the period reached SEK 279.8 million (SEK -32.7 m)
